阿帕替尼联合mFOLFOX6化疗对ⅢB期、Ⅳ期胃癌患者疗效及血清肿瘤标志物水平的影响

Effect of Apatinib Combined with mFOLFOX6 Chemotherapy on Therapeutic Effect and Serum Tumor Markers in Patients with StageⅢB,StageⅣGastric Cancer

目的:探讨阿帕替尼联合mFOLFOX6化疗(亚叶酸钙、氟尿嘧啶联合奥沙利铂)对ⅢB期、Ⅳ期胃癌患者疗效及血清肿瘤标志物水平的影响。方法:选取2017年12月—2019年10月靖江市人民医院收治的102例ⅢB期、Ⅳ期胃癌患者作为研究对象,采用随机数表法将患者分为联合组(阿帕替尼联合mFOLFOX6化疗)与参照组(mFOLFOX6化疗治疗),各51例。比较两组治疗效果、血管内皮生长因子(VEGF)、胰岛样素生长因子1(IGF-1)、生存时间、不良反应。结果:联合组总有效率高于参照组,差异有统计学意义(P<0.05);治疗后,两组血清IGF-1、VEGF水平较治疗前降低,且联合组低于参照组,差异有统计学意义(P<0.05);联合组总平均生存时间长于参照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿帕替尼联合mFOLFOX6化疗对ⅢB期、Ⅳ期胃癌患者疗效显著,可明显降低血清IGF-1、VEGF水平,延长总平均生存时间,且安全可靠。

Objective:To explore the effec of Apatinib combined with mFOLFOX6 chemotherapy(Calcium Folinate,Fluorouracil and Oxaliplatin)on therapeutic effect and serum tumor markers in patients with stageⅢB,stageⅣgastric cancer.Method:A total of 102 patients with stageⅢB,stageⅣgastric cancer who admitted to Jingjiang People's Hospital from December 2017 to October 2019 were selected as the research objects,the patients were divided into the combined group(Apatinib combined with mFOLFOX6 chemotherapy)and the reference group(mFOLFOX6 chemotherapy)by random number table method,with 51 cases in each group.The therapeutic effect,vascular endothelial growth factor(VEGF)and insulin-like growth factor 1(IGF-1),survival time and adverse reactions were compared between two groups.Result:The total effective rate in the combined group was higher than that in the reference group,the difference was statistically significant(P<0.05);after treatment,the levels of serum IGF-1 and VEGF in two groups were lower than those before treatment,and those in the combined group were lower than those in the reference group,the differences were statistically significant(P<0.05);the total average survival time of the combined group was longer than that of the reference group,and the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Apatinib combined with mFOLFOX6 chemotherapy has significant efficacy in patients with stageⅢB,stageⅣgastric cancer,it can significantly decrease serum IGF-1 and VEGF levels,prolong the total mean survival time,and is safe and reliable.